Skip to main content

Advertisement

Table 4 Percent of heteroplasmy calls out of total number of sequence variants.

From: Performance of mitochondrial DNA mutations detecting early stage cancer

Genomes sequenced Number of sequence variants Number (%) of heteroplsmy sequence variants Number (%) of specimens with heteroplasmy
Blood from patients with cancer – 26 391 27 (6.9%)* 18 (69.2%)*
Tumor – 24 411 43 (10.5%)* 18 (75.0%)*
BF from patients with cancer – 22 293 11 (3.8%) 7 (31.8%)
Blood from individuals without cancer -12 202 7 (3.5%) 4 (33.3%)
Sputum from individuals without cancer – 12 206 11 (5.3%) 5 (41.7%)
  1. *: Statistically significant difference from non-cancer population and BF